Sabby Management’s Solid Biosciences SLDB Stock Holding History

Sabby Management’s Portfolio SLDB Stock Details SLDB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q2	–	Sell	-1,667	Closed	-$188K	–	177
2018 Q1	$188K	Buy	+1,667	New	+$563K	0.02%	122

Other funds holding SLDB

JP Morgan Chase

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return

Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

Sabby Management's SLDB Position: Q2 2018 in Review

Sabby Management sold out of Solid Biosciences (SLDB) in Q2 2018, closing a stake of 1,667 shares — an estimated $188K sold.

Sabby Management first reported a position in SLDB in Q1 2018 and held it in 1 quarter. The position peaked at $188K in Q1 2018. 64 funds tracked by Wall St. Rank hold SLDB as of Q2 2018.

Sabby Management reported no remaining Solid Biosciences position as of Q2 2018 after selling out during the quarter.
Sabby Management sold 1,667 Solid Biosciences shares in Q2 2018, an estimated $188K.
Sabby Management first reported a position in Solid Biosciences in Q1 2018 and held it in 1 quarter.
Sabby Management's Solid Biosciences position peaked at $188K in Q1 2018.
64 funds tracked by Wall St. Rank held Solid Biosciences as of Q2 2018.

Based on Sabby Management's 13F filing for Q2 2018, filed 14 Aug 2018.